SRPT
Sarepta Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-02
Figures on this page computed 2026-11-08 12:48 UTC
Last close
18.99USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-02
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-02
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
-32.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
-14.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
0.91Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.38 against 0.58 on the market's range.
- Growth32.4%48 of 100, below its sector
- Returns on capital-62.5%19 of 100, below its sector
- Margins98.8%43 of 100, above its sector
- Price1.6x62 of 100, above its sector
- Safety0.9138 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 2- Profit on each unit of sales-32.5%-85.4%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years32.4%20.0%Ahead
Higher is better here.
- Debt against equity0.91n/an/a
Lower is better here.
- Gross margin98.8%n/an/a
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Ultragenyx Pharmaceutical Inc., SRPT is behind on 0 of 2 measures.
Against Ultragenyx Pharmaceutical Inc., SRPT is behind on 0 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-02
Profit on each unit of sales-32.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
Sales growth over five years32.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
Debt against equity0.91
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
Gross margin98.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-084144
- Reported in
- USD